Medicine Matters oncology

JAK inhibitors, such as ruxolitinib (Jakafi®), represent a new mechanistic class of drug that may have activity in CTCL. Recent evidence suggests that mutations in the JAK/STAT pathway may contribute to formation of CTCL and thus targeting these mutated JAK kinases may potentially have therapeutic activity [28]. A phase II trial is underway studying ruxolitinib in relapsed or refractory TCLs.